India Globalization Capital Inc Asset Resilience Ratio
India Globalization Capital Inc asset resilience ratio. India Globalization Capital Inc (IGC) has an Asset Resilience Ratio of 11.60% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See India Globalization Capital Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of India Globalization Capital Inc (2006–2025)
Asset resilience ratio of India Globalization Capital Inc from 2006 to 2025. This chart shows how India Globalization Capital Inc's Asset Resilience Ratio has changed over time. Read IGC liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down India Globalization Capital Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is India Globalization Capital Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $1.10 Million | 11.34% |
| Short-term Investments | $25.00K | 0.26% |
| Total Liquid Assets | $1.13 Million | 11.60% |
Asset Resilience Insights
- Moderate Liquidity: India Globalization Capital Inc has 11.60% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
India Globalization Capital Inc Industry Peers by Asset Resilience Ratio
Compare India Globalization Capital Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
India Globalization Capital Inc Asset Resilience Ratio by Year (2006–2025)
India Globalization Capital Inc asset resilience ratio by year from 2006 to 2025. The table below shows the annual Asset Resilience Ratio data for India Globalization Capital Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 4.63% | $405.00K | $8.75 Million | -7.47pp |
| 2024-03-31 | 12.10% | $1.20 Million | $9.90 Million | -7.40pp |
| 2023-03-31 | 19.50% | $3.35 Million | $17.18 Million | -19.48pp |
| 2022-03-31 | 38.98% | $10.46 Million | $26.83 Million | -1.80pp |
| 2021-03-31 | 40.78% | $14.63 Million | $35.87 Million | -1.79pp |
| 2020-03-31 | 42.57% | $12.34 Million | $28.98 Million | -34.00pp |
| 2019-03-31 | 76.57% | $26.39 Million | $34.47 Million | +59.93pp |
| 2018-03-31 | 16.65% | $1.81 Million | $10.85 Million | -4.78pp |
| 2017-03-31 | 21.43% | $2.42 Million | $11.28 Million | +21.34pp |
| 2016-03-31 | 0.09% | $17.17K | $18.86 Million | -0.15pp |
| 2015-03-31 | 0.24% | $49.54K | $20.33 Million | +0.04pp |
| 2014-03-31 | 0.20% | $35.69K | $17.73 Million | +0.11pp |
| 2013-03-31 | 0.09% | $16.85K | $19.25 Million | -- |
| 2012-03-31 | 0.00% | $0.00 | $25.26 Million | -- |
| 2008-03-31 | 4.44% | $3.00 Million | $67.63 Million | -89.08pp |
| 2007-03-31 | 93.52% | $66.10 Million | $70.69 Million | -6.33pp |
| 2006-03-31 | 99.84% | $65.83 Million | $65.93 Million | -- |
About India Globalization Capital Inc
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatm… Read more